Sign up to save your podcasts
Or
Share Treating and Managing Chronic Myeloid Leukemia (CML) in 2025: Dr. Jorge Cortes
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Treating and Managing Chronic Myeloid Leukemia (CML) in 2025: Dr. Jorge Cortes
In this episode of the Oncology Brothers podcast, we welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss the latest updates in the management of Chronic Myeloid Leukemia (CML).
Join us as we dive into the essential aspects of CML treatment, including:
• The importance of initial workup and bone marrow biopsy in diagnosing CML.
• Risk stratification and the selection of first-line therapies, including the latest TKIs like Asiminib and Ponatinib.
• Patient-centered decision-making and how to align treatment options with individual patient goals.
• Monitoring for response using BCR-ABL titer and the role of minimal residual disease (MRD).
• The significance of managing side effects associated with various TKIs, including cardiovascular risks and unique toxicities.
• Insights into the role of transplant in accelerated and blast phases of CML.
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of CML treatment.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and tune in for more episodes on treatment algorithms, FDA approvals, and conference highlights.
#CML #TKIs #Asciminib #Imatinib #Pontatinib #Bosutinib #Dasatinib #Nilotinib #BCR-ABL #Hematology #OncologyBrothers #JorgeCortes
View all episodes
By Oncology Brothers
4.8
3939 ratings
In this episode of the Oncology Brothers podcast, we welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss the latest updates in the management of Chronic Myeloid Leukemia (CML).
Join us as we dive into the essential aspects of CML treatment, including:
• The importance of initial workup and bone marrow biopsy in diagnosing CML.
• Risk stratification and the selection of first-line therapies, including the latest TKIs like Asiminib and Ponatinib.
• Patient-centered decision-making and how to align treatment options with individual patient goals.
• Monitoring for response using BCR-ABL titer and the role of minimal residual disease (MRD).
• The significance of managing side effects associated with various TKIs, including cardiovascular risks and unique toxicities.
• Insights into the role of transplant in accelerated and blast phases of CML.
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of CML treatment.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and tune in for more episodes on treatment algorithms, FDA approvals, and conference highlights.
#CML #TKIs #Asciminib #Imatinib #Pontatinib #Bosutinib #Dasatinib #Nilotinib #BCR-ABL #Hematology #OncologyBrothers #JorgeCortes
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
JAMA Editors' Summary
136 Listeners
NEJM This Week
323 Listeners
Journal of Clinical Oncology (JCO) Podcast
39 Listeners
Research To Practice | Oncology Videos
116 Listeners
JAMA Clinical Reviews
501 Listeners
ASCO Daily News
57 Listeners
JAMA Medical News
88 Listeners
Core IM | Internal Medicine Podcast
1,144 Listeners
The ONS Podcast
200 Listeners
OncoPharm
184 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
The Clinical Problem Solvers
514 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
185 Listeners